Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 35.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 430,612 shares of the biopharmaceutical company’s stock after selling 234,110 shares during the period. Pictet Asset Management Holding SA owned 0.33% of Alnylam Pharmaceuticals worth $101,327,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cerity Partners LLC grew its position in shares of Alnylam Pharmaceuticals by 133.6% in the 3rd quarter. Cerity Partners LLC now owns 13,019 shares of the biopharmaceutical company’s stock worth $3,581,000 after acquiring an additional 7,445 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals in the third quarter worth $45,000. Quantbot Technologies LP increased its stake in Alnylam Pharmaceuticals by 1,754.5% during the third quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 193 shares during the last quarter. Bridgewater Associates LP acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $551,000. Finally, Blueshift Asset Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $293,000. 92.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

ALNY has been the subject of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Bank of America upped their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a report on Friday, March 21st. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Scotiabank upped their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a research note on Friday, March 21st. Finally, Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $312.30.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 in the last three months. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $268.46 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a 50-day moving average of $259.86 and a two-hundred day moving average of $260.50. The company has a market capitalization of $34.92 billion, a price-to-earnings ratio of -123.71 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.